Kathrine O'Brien - 03 Nov 2023 Form 4 Insider Report for Tabula Rasa HealthCare, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Nov 2023, 18:11:53 UTC
Prior SEC filing: 13 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Brian W. Adams, by Power of Attorney

Key filing fact

Kathrine O'Brien filed Form 4 for Tabula Rasa HealthCare, Inc. on 14 Nov 2023.

Key facts

This page summarizes Kathrine O'Brien's Form 4 filing for Tabula Rasa HealthCare, Inc..
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Nov 2023, 18:11.

Change

Previous filing in this sequence was filed on 13 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRHC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -20,879
Change %: -22%
Price
Shares after: 75,810
Date: 03 Nov 2023
Ownership: Direct
Footnotes: F1

TRHC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -50,169
Change %: -66%
Price
Shares after: 25,641
Date: 03 Nov 2023
Ownership: Direct
Footnotes: F2

TRHC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -25,641
Change %: -100%
Price
Shares after: 0
Date: 03 Nov 2023
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Kathrine O'Brien is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 20,879 shares of common stock of the Company ("Common Stock") were converted into the right to receive a cash payment of $219,229.50, representing the product obtained by multiplying (x) the number of shares of Common Stock owned by the reporting person, by (y) the offer price ($10.50).

Footnote F2

Upon the consummation of the Merger, pursuant to the Merger Agreement, 50,169 outstanding restricted stock units ("RSUs") were cancelled and converted into the right to receive a cash payment of $526,774.50, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock underlying the RSUs, by (y) the offer price ($10.50).

Footnote F3

Upon the consummation of the Merger, pursuant to the Merger Agreement, 25,641 unvested restricted stock awards ("RSAs") were cancelled and converted into the right to receive a cash payment of $269,230.50, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock underlying the RSAs, by (y) the offer price ($10.50).